Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.67 |
| ▸ | RAB9A | P51151 | 4/20 | 0.67 |
| ▸ | NPC1 | O15118 | 4/20 | 0.67 |
| ▸ | LMNA | P02545 | 5/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.62 |
| ▸ | MAOB | P27338 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | GFER | P55789 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17887994 | 0.91 | SMN1; SMN2 (0.77) | SMN1; SMN2RAB9ANPC1LMNAALDH1A1 | |
| SCHEMBL10005048 | 0.89 | GPR139 (0.58) | SMN1; SMN2RAB9ANPC1LMNACYP1A2 | |
| SCHEMBL10099538 | 0.87 | HDAC3 (0.61) | SMN1; SMN2RAB9ANPC1LMNACYP1A2 | |
| SCHEMBL6570929 | 0.84 | SMN1; SMN2 (0.69) | SMN1; SMN2RAB9ANPC1LMNAALDH1A1 | |
| SCHEMBL17301589 | 0.84 | SMN1; SMN2 (0.69) | SMN1; SMN2RAB9ANPC1LMNACYP1A2 | |
| SCHEMBL24648929 | 0.84 | SMN1; SMN2 (0.69) | SMN1; SMN2RAB9ANPC1LMNAALDH1A1 | |
| SCHEMBL14297350 | 0.84 | NPC1 (0.69) | SMN1; SMN2RAB9ANPC1LMNAMEN1 | |
| SCHEMBL9584535 | 0.83 | CYP1A2 (0.78) | SMN1; SMN2RAB9ANPC1LMNACYP1A2 | |
| SCHEMBL26766869 | 0.83 | RAB9A (0.65) | SMN1; SMN2RAB9ANPC1LMNACYP1A2 | |
| SCHEMBL10494518 | 0.83 | SMN1; SMN2 (0.60) | SMN1; SMN2RAB9ANPC1LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9193728-B2 | Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-9051314-B2 | Bridged heterocyclic compounds and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-9034869-B2 | Bridged heterocyclic compounds and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-05-19 | — | — | US | disclosed |
| US-20140024643-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-01-23 | — | — | US | disclosed |
| US-20130184269-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-8093227-B2 | Monosaccharide compounds and methods therefor | ALCHEMIA PTY LTD (AU) | 2012-01-10 | — | — | US | disclosed |
| US-20100184607-A1 | MONOSACCHARIDE COMPOUNDS AND METHODS THEREFOR | ALCHEMIA PTY LTD. (AU) | 2010-07-22 | — | — | US | disclosed |
| US-7417129-B2 | Combinatorial libraries of monosaccharides | ALCHEMIA PTY LTD (AU) | 2008-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140024643-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | HRH4, HNMT, HTR2C | SMN1; SMN2 3057/4885RAB9A 648/4885NPC1 2839/4885 |
| US-20130184269-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | HRH4, HNMT, HTR2C | SMN1; SMN2 3057/4885RAB9A 648/4885NPC1 2839/4885 |
| US-20100184607-A1 | MONOSACCHARIDE COMPOUNDS AND METHODS THEREFOR | SLC5A1, UGGT1, MRPL21 | SMN1; SMN2 3629/4885RAB9A 3533/4885NPC1 969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.